Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Table 3

The change of glucose metabolism-related variables after SSA treatment among the Improved/Stable/Deteriorated groups.

Reduction (post-SSA)—basal	Improved ()	Stable ()	Deteriorated ()	value
GHm (μg/l)	−28.01 (−53.71~−10.80)	−15.55 (−32.89~−6.50)	−5.89 (−16.55~−1.69)	0.021^∧
IGF-1 index	−0.64 (−1.40~−0.26)	−1.16 (−1.44~−0.42)	−0.60 (−1.58~−0.18)	0.353
HOMA-IR	−0.75 (−4.15~0.00)	−1.45 (−2.98~−0.28)	−1.17 (−2.41~0.26)	0.830
ISOGTT	26.01 (5.16~54.78)	26.01 (5.23~53.45)	15.13 (0.54~51.43)	0.781
HOMA-β (%)	−56.15 (−103.77~−4.03)^∗	−36.94 (−140.44~0.03)^∗	−85.52 (−206.70~−65.53)	0.074
INS0/BG0	−0.78 (−2.65~−0.14)	−0.64 (−1.66~0.13)	−1.16 (−3.14~−0.81)	0.121
IGI/IR	−1.26 (−4.46~0.14)	−0.47 (−6.36~0.13)	−2.28 (−7.23~0.19)	0.844
ISSI2	36.16 (−118.62~113.34)	−15.97 (−59.98~54.94)	−84.97 (−158.72~100.10)	0.319
IGI	−17.10 (−28.02~−5.78)	−1.79 (−30.96~0.07)	−18.69 (−41.77~−5.24)	0.350
AUCINS/AUCBG	−4.76 (−10.44~−1.96)	−2.42 (−8.32~0.43)	−4.40 (−13.00~−1.93)	0.244

IGF-1 index: the ratio of the measured IGF-1 value to the upper limit of normal (ULN); HOMA-IR: indicator of insulin resistance; IS_OGTT: the OGTT insulin sensitivity index; HOMA-β: homeostatic model assessment of pancreatic beta-cell function; INS₀: fasting plasma insulin; BG₀: fasting plasma glucose; IGI: insulinogenic index; AUC_BG: the areas under the curve of glucose; AUC_INS: the areas under the curve of insulin; ISSI2: the OGTT insulin secretion sensitivity index-2. values are for variations before and after SSA treatment; versus the Deteriorated group; .